Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKST02 in Relapsed or Refractory Multiple Myeloma
NCT07695740Phase 2Not yet recruiting
- Sponsor
- Excyte Biopharma Ltd
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of YKST02 in multiple myeloma (MM), sponsored by Excyte Biopharma Ltd. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
YKST02
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07695740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695740.